Ensysce Biosciences Inc (ENSC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2023 | 12-2022 | 09-2022 | 06-2022 | 03-2022 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 1,416 | 3,148 | N/A | 3,735 | 8,441 |
| Receivables | 289 | 277 | N/A | 277 | 809 |
| Other current assets | 19 | 27 | 0 | 10 | 18 |
| TOTAL | $3,371 | $5,299 | $N/A | $7,195 | $11,658 |
| Non-Current Assets | |||||
| Other Non-Current Assets | 544 | 586 | 0 | 754 | 713 |
| TOTAL | $544 | $586 | $N/A | $754 | $713 |
| Total Assets | $3,915 | $5,885 | $N/A | $7,949 | $12,372 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 1,598 | 2,944 | 0 | 3,048 | 960 |
| Accrued Expenses | 2,359 | 2,227 | N/A | 2,671 | 1,752 |
| Other current liabilities | N/A | N/A | 800 | N/A | N/A |
| TOTAL | $3,976 | $9,464 | $800 | $8,249 | $8,802 |
| Non-Current Liabilities | |||||
| Long Term Debt | N/A | 140 | N/A | 137 | 1,587 |
| Other Non-Current Liabilities | 95 | 298 | 22 | 387 | 871 |
| TOTAL | $91 | $451 | $N/A | $498 | $2,458 |
| Total Liabilities | $4,067 | $9,915 | $800 | $8,747 | $11,260 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 86 | 86 | 16 | 10 | 10 |
| Common Shares | 0 | 0 | N/A | 4 | 3 |
| Retained earnings | -113,127 | -110,931 | N/A | -95,512 | -87,512 |
| Other shareholders' equity | -319 | -315 | 0 | -306 | -280 |
| TOTAL | $-152 | $-4,030 | $N/A | $-798 | $1,111 |
| Total Liabilities And Equity | $3,915 | $5,885 | $800 | $7,949 | $12,372 |